Scripps Research Logo

The Gallay Laboratory


201820172016 | 20152014 |  2013 |  2012 |  2011 |  2010 |  2009 |  2008 |  2007 |  2006 |  2005 |  2004 |  2003



Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Pyles RB, Baum MM, Moss JA. 2018. Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice. Open Virol J. Feb 28;12:1-13.



Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles RB, Marzinke MA, Moss JA, Baum MM. 2017. Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. PLoS One. Sep 7;12(9):e0184303. 


Chatterji U, Bobardt M, Schaffer L, Wood M,  Gallay PA. 2016. Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.  PLoS One. 11(7):e0159511.

Gallay PA,Chatterji U, Bobardt MD, Long Z, Zhang S, Su Z. 2016. Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175.  PLoS One. 11(4):e0152036.


Chatterji U, Bobardt M, Tai A, Wood M, & Gallay PA. 2015. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories. Antimicrob Agents Chemother.  59(5):2496-2507.

Gallay PA, Bobardt MD, Chatterji U, Trepanier DJ, Ure D, Ordonez C, & Foster R. 2015. The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action. PLoS One. 10(8): e0134707.

Hansson MJ, Moss SJ, Bobardt M, Chatterji U, Coates N, Garcia-Rivera JA, Elmer E, Kendrew S, Leyssen P, Neyts J, Nur EAM, Warneck T, Wilkinson B, Gallay P, & Gregory MA. 2015. Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection. Chem Biol. 22(2):285-292.

Hopkins S, & Gallay PA. 2015. The role of immunophilins in viral infection. Biochim Biophys Acta. 1850(10):2103-2110.

Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R, Gallay P, & Naoumov NV. 2015. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production. Gastroenterology. 148(2):403-414.e407.

Veazey RS, Chatterji U, Bobardt M, Russell-Lodrigue KE, Li J, Wang X, & Gallay PA. 2015. C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge. Antimicrob Agents Chemother. 60(1):693-698.


Lim PJ,  Gallay PA. 2014. Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol. 8C:30-37.

Chatterji U, Garcia-Rivera JA, Baugh J, Gawlik K, Wong KA, Zhong W, Brass CA, Naoumov NV,  Gallay PA. 2014. The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance. Antimicrob Agents Chemother. 58(6):3327-3334.

Gawlik K,  Gallay PA. 2014. HCV core protein and virus assembly: what we know without structures. Immunol Res. 60(1):1-10.

Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD, Gallay PA. 2014. HCV core residues critical for infectivity are also involved in core-NS5A complex formation. PLoS One. 9(2):e88866.

Gallay P. 2014. Resistance to Cyclophilin Inhibitors. In M. Gotte, A. Berghuis, G. Matlashewski, M. Wainberg, & D. Sheppard (Eds.), Handbook of Antimircrobial Resistance: 1-24.

Chamoun-Emanuelli AM, Bobardt M, Moncla B, Mankowski MK, Ptak RG,  Gallay P, & Chen Z. 2014. Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide. Antimircrob Agents Chemother. 58(2): 687-697.

Bobardt M, Chatteriji U, Lim P, Gawlik K, & Gallay P. 2014. Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activaion in HCV-Infected Cells. Open Virol J. 8:1-8.


Baugh JM, Garcia-Rivera JA,  Gallay PA. 2013. Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res. 100(2):555-561.

Gallay PA, Ptak RG, Bobardt MD, Dumont JM, Vuagniaux G, Rosenwirth B. 2013. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms. Viruses. 5(3):981-97.

Gallay PA, Lin K. 2013. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther. 7:105-115.


Hopkins, S., DiMassimo, B, Rusnak, P., Heuman, D., Lalezari, J., Sluder, A.,  Scorneaux, B., Mosier, S., Kowalczyk, P., Ribeill, Y., Baugh, J., and  Gallay, P.A. 2012. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol.  56(7):3888-3897.

Maskiewicz, R., Bobardt, M., Chatterji, U., Gunaseelan, S., Dezzutti, C.S., Penin, F., and  Gallay , P.A. 2012. Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities. Antimicrobial Agents and Chemotherapy.  56(6):3336-3343.

Selvarajah, S. Chatterji, U., Kuhn, R., Kinney, Vasudevan, S. G., and  Gallay, P.A. 2012. Development and evaluation of an enzyme-linked immunosorbent assay for Dengue capsid. The Open Virology Journal. 6:29-37.


Gallay, P.A. 2011. Cyclophilin inhibitors: a novel class of promising host targeting anti-HCV agents.  Immunologic Research. 13(3):403-417.

de Witte, L., Bobardt, M.D, Chatterji, U., van Loenen, F.B., Verjans, G.M., Geijtenbeek, T.B.H. and  Gallay, P.A. 2011. HSV Neutralization by the Microbicidal Candidate C5A.  PLoS One, 6(5):e18917.

Gregory, M.A., Moss, S. J., Coates, N., Foster, T., Bobardt, M., Chatterji, U.,  Gallay, P. A., Leyssen, P., Neyts, J., Nur-E-Alam, M., Piraee, M., Suthar, D., Warneck, T., Zhang, M.-Q., and Wilkinson, B. 2011. Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.  Antimicrobial Agents and Chemotherapy, 55:1975-1981.

Foster, T.,  Gallay, P.A., Stonehouse, N. and Harris, M. 2011. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner.  J. of Virol. 85:7460-7464.

Chamoun AM, Chockalingam K, Bobardt M, Simeon R, Chang J,  Gallay P., Chen Z. 2011. PD 404,182 is a virucidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus. Antimicrobial Agents and Chemotherapy.  56(2):672-681.

Moss SJ, Bobardt M, Leyssen P, Coates N, Chatterji U, Dejian X, Foster T, Liu J, Nur-e-Alam M, Suthar D, Yongsheng C, Warneck T, Neyts J,  Gallay P., Wilkinson B, Gregory MA. 2011. Sangamides, a new class of cyclophilin inhibiting host targeted antivirals for treatment of HCV infection. Med. Chem. Commun. 3:944-949.


Waller, H., Chatterji, U.,  Gallay, P., Parkinson, T., Targett-Adams, P. 2010. The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A.   J. Virol. Methods 165:202-210.

Bobardt, M.D., Chatterji, U., Schaffer, L., de Witte, L., and  Gallay, P.A., 2010. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent.  Antimicrobial Agents and Chemotherapy, 54:2753-2766.

Chatterji, U., Lim, P., Bobardt, M.D., Wieland, S., Cordek, D.G., Vuagniaux, G., Chisari, F., Cameron, C.E., Targett-Adams, P., Parkinson, T., and  Gallay, P.A. 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors.   J. Hepatol., 53:50-56.

Chatterji, U., Bobardt, M.D., Lim, P.,  Gallay, P.A. 2010. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.  J. Gen. Virol. 91:1189-1193.

Fischer, G.,  Gallay, P.A., Hopkins, S. Cyclophilin inhibitors for the treatment of hepatitis C virus infection. 2010. Curr. Opin. Investig.  Drugs, 11:911-918.

Coelmont, L., Chatterji, U., Hanoulle, X., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., Vuagniaux, G., Bartenschlager, R.,  Gallay, P.A., Lippens, G., and Neyts, J. 2010. Debio 025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A.  PLoS One, 5:e13687.


Chatterji, U., Bobardt, M., Selvarajah, S., Yang,F., Tang, H. Sakamoto, N Vuagniaux, G., Parkinson, T., and  Gallay, P. 2009. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.   J. Biol. Chem. 284:16998-17005.

Gallay, P.A. 2009. Cyclophilin inhibitors.  Clin. Liver Dis. 13:403-417.


Cheng, G., Montero, A., Gastaminza, P., Whitten-Bauer, C., Wieland, S. F., Isogawa, M. Fredericksen, B., Selvarajah, S.,  Gallay, P., Ghadiri, R., and Chisari, F. V.  2008. A virocidal amphipathic alpha-helical peptide that inhibits hepatitis C virus infection in vitro.  Proc. Natl. Acad. Sci. 105:3088-3093.

Bobardt, M., Cheng, G., de Witte, L., Selvarajah, S., Chatterji, U., Beer, B., Geijtenbeek, T. B. H., Chisari, F. V., and  Gallay, P. A.  2008. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus.  Proc. Natl. Acad. Sci. USA 105: 5525-5530.

Flisiak, R., Horban, A.,  Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., Siwak, A., Cielniak, I., Higersberger, J., Kierkus, J., Aeschlimann, C., Grosgurin, P., Nicolas-Métral, V., Dumont, J.-M., Porchet, H., Crabbé, R., and Scalfaro, P.  2008. The cyclophilin inhibitor Debio 025 shows potent anti-HCV effect in a double-blind, placebo-controlled study in HIV/HCV infected patients.   Hepatology. 47:817-826.

Ptak, R.,  Gallay, P. A., Jochmans, D., Halestrap, A. P.,  Ruegg, U. T., Pallansch, L. A., Bobardt, M. D., De Bethune, M.-P., Neyts, J., De Clercq,E., Dumont, J.-M., Scalfaro, P., Besseghir, K., Wenger, R. M., and Rosenwirth, B. 2008. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.   Antimicrob. Agents Chemother. 52: 1302-1307.


Bobardt, M.D., Chatterji, U., Selvarajah, S., Van der Schueren B., David, G., Kahn, B. and  Gallay, P.A.  2007. Cell-free HIV-1 transcytosis through primary genital epithelial cells.  J. Virol. 81:395-405.

de Witte, L., Bobardt, M.D., Chatterji, U., Degeest, G., David, G., Geijtenbeek, T.B.H., and  Gallay, P. A.  2007. Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1.   Proc. Natl. Acad. Sci. 104: 19464-1949.


Chatterji, U., Bobardt, M.D., Gaskill, P., Sheeter, D., Fox, H. and  Gallay P.A. 2006. Trim 5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.   J. Biol. Chem. 281:37025-37033.


de Parseval, A., Bobardt, M.D., Chatterji, A., Chatterji, U., Elder, J.H, David, G., Zolla-Pazner, S., Farzan, M., Lee, T.-H. and  Gallay, P.A.   2005. A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs.   J. Biol. Chem. 280:39493-39504.

Chatterji, U., Bobardt, M.D., Stanfield, R., Ptak, R.G., Pallansch, L.A., Ward, P.A., Jones, M.J., Stoddart, C.A., Scalfaro, P., Dumont, J.M., Besseghir, K., Rosenwirth, B. and  Gallay, P.A.  2005. Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in owl monkey cells.   J. Biol. Chem. 280:40293-40300.


Gallay, P.A.
  2004. Syndecans and HIV-1 pathogenesis.   Microbes and Infection 6:617-622.

Bobardt, M.D., Salmon, P., Wang, L., Esko, J.D., Gabuzda, D., Fiala, M., Trono, D., Van der Schueren, B., David, G. and  Gallay, P.A.  2004. Contribution of proteoglycans to HIV-1 brain invasion.   J. Virol. 78:6567-6584.

Bobardt, M.D., Armand-Ugón, M., Clotet, I., Zhang, Z., David, G., Este, J.A. and  Gallay, P.A.  2004. Effect of polyanion-resistance on HIV-1 infection.   Virology 325:389-398.


Bobardt, M.D., Saphire, A.C.S., Hung, H-C., Yu, X., Van der Schueren, B., Zhang, Z., David, G. and  Gallay, P.A.  2003. Syndecan captures, protects and transmits HIV-1 to T-lymphocytes.   Immunity 18:27-39.